|Bid||24.98 x 1300|
|Ask||25.00 x 900|
|Day's Range||23.59 - 25.20|
|52 Week Range||6.75 - 39.50|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.50|
Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the publication of the European and Canadian Phase III head-to-head pivotal trial results in the April issue of Aesthetic Surgery Journal. “We are pleased that these data were accepted and published in the Aesthetic Surgery Journal, which is added validation of the rigor of the study,” said Rui Avelar, MD, Chief Medical Officer and Head of Research & Development. “The results of this study are compelling and reinforce the clinical performance of Jeuveau™, which is the first 900 kDa product to enter the U.S. market in nearly 30 years,” said David Moatazedi, President and Chief Executive Officer.
Nuceiva™ (branded Jeuveau™ in the United States) is being evaluated by the EMA for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age. “We are actively addressing the CHMP’s final few questions in accordance with their timelines, which will enable them to adopt their formal opinion on our MAA during the April Committee meeting,” said Rui Avelar, MD, Chief Medical Officer and Head of Research & Development at Evolus, Inc. “In the second quarter, in addition to an opinion in Europe, we look forward to publishing the largest head-to-head aesthetic pivotal trial of our neurotoxin versus BOTOX®, which was conducted in Europe and Canada.
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the publication of the U.S. Phase III pivotal trial results for Jeuveau™ in Dermatologic Surgery. The article titled, “Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results from 2 Identical Phase III Studies”, is now available on the Journal’s Website and will be printed in the March 2019 issue. “As a principal investigator in EV-001 and EV-002, and first author on the paper, I am confident in the robustness of these results.
Received U.S. FDA Approval of Jeuveau™ on February 1, 2019 Majority of Sales Force Hired with Launch Planned in the Coming Weeks Hosting Investor & Analyst Day on May 8th,.
NEWPORT BEACH, Calif., March 18, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
IRVINE, Calif., March 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
Evolus, Inc.'s (NASDAQ:EOLS): Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. With the latest financial year loss of -US$4.5m and a trailing-twelve monthRead More...
NEWPORT BEACH, Calif., Feb. 27, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on delivering breakthrough products, today announced the appointment.
Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
Here are two stocks moving higher on news and two others showing weakening technical indicators. American Superconductor (AMSC) jumped 66 cents to $14.54 Thursday on 604,100 shares traded, or double the average volume.
In his second "Executive Decision" segment of Mad Money Thursday night, Jim Cramer sat down with David Moatazedi, president and CEO of Evolus Inc. with a new drug to compete with Botox. Shares of EOLS have surged from $16 to $29 after the company received FDA approval on Friday.
Billionaire David Tepper, president of hedge fund Appaloosa LP, fired off a letter Tuesday demanding the Dublin-based pharmaceutical firm separate the roles of chairman and CEO. Following the release of the letter, Allergan's stock fell 0.4% Tuesday to close at $138.01. "The Board of Directors is committed to strong governance practices and independent board leadership," Allergan said in its statement.
Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
Stocks that moved substantially or traded heavily on Monday: Papa John's International Inc., up $ 3.46 to $41.97 The head of the investment firm Starboard Value is being named board chairman at the troubled ...
shares fell almost 4% and Evolus Inc. shares gained almost 12% Monday after the U.S. Food and Drug Administration approved Evolus's new wrinkle treatment for adult patients which is expected to rival Allergan's Botox. The treatment, called Jeuveau, received FDA approval late Friday, some eight months after the agency first rejected the application citing deficiencies in its manufacturing and chemical composition.
Jim Cramer hears from Evolus President and CEO David Moatazedi about his company's cheaper rival to Allergan's Botox.